INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $24,000 | +9.1% | 30,000 | +3.4% | 0.00% | – |
| Q2 2020 | $22,000 | -12.0% | 29,000 | -6.5% | 0.00% | -100.0% |
| Q1 2020 | $25,000 | -16.7% | 31,000 | +3.3% | 0.00% | 0.0% |
| Q4 2019 | $30,000 | +11.1% | 30,000 | -3.2% | 0.00% | 0.0% |
| Q3 2019 | $27,000 | -3.6% | 31,000 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $28,000 | 0.0% | 31,000 | +10.7% | 0.00% | 0.0% |
| Q1 2019 | $28,000 | -3.4% | 28,000 | -12.5% | 0.00% | 0.0% |
| Q4 2018 | $29,000 | -14.7% | 32,000 | -5.9% | 0.00% | 0.0% |
| Q3 2018 | $34,000 | +17.2% | 34,000 | +3.0% | 0.00% | 0.0% |
| Q2 2018 | $29,000 | +11.5% | 33,000 | +3.1% | 0.00% | 0.0% |
| Q1 2018 | $26,000 | 0.0% | 32,000 | -5.9% | 0.00% | 0.0% |
| Q4 2017 | $26,000 | 0.0% | 34,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $26,000 | -31.6% | 34,000 | -12.8% | 0.00% | 0.0% |
| Q2 2017 | $38,000 | +5.6% | 39,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $36,000 | – | 39,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Silver Point Capital L.P. | 57,420,000 | $44,527,000 | 5.17% |
| Birch Grove Capital LP | 10,003,000 | $7,934,000 | 4.14% |
| PenderFund Capital Management Ltd. | 9,605,000 | $9,491,000 | 2.41% |
| Context Capital Management, LLC | 9,887,000 | $7,671,000 | 1.05% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $45,738,000 | 0.90% |
| DeepCurrents Investment Group LLC | 35,892,000 | $27,953,000 | 0.74% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 22,977,000 | $18,267,000 | 0.70% |
| WHITEBOX ADVISORS LLC | 23,150,000 | $17,847,000 | 0.56% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 27,397,000 | $21,720,000 | 0.46% |
| OAKTREE CAPITAL MANAGEMENT LP | 19,435,000 | $15,079,000 | 0.26% |